

Matthew W Jenner

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7284378/matthew-w-jenner-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73
papers

1,923
citations

21
h-index

43
g-index

73
ext. papers

2,307
ext. citations

4.6
avg, IF

4.01
L-index

#	Paper	IF	Citations
73	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022 , 108, 73-83	3.8	1
72	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102228	2.2	5
71	Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FITNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. <i>BMJ Open</i> , 2022 , 12, e056147	3	0
70	Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. <i>Haematologica</i> , 2021 , 106, 1957-1967	6.6	6
69	Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. <i>Leukemia</i> , 2021 , 35, 2043-2053	10.7	10
68	MUK OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. <i>BMJ Open</i> , 2021 , 11, e046225	3	5
67	Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK Four Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 154-161.e3	2	4
66	Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 667-675	2	1
65	Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. <i>British Journal of Haematology</i> , 2021 , 193, 551-555	4.5	11
64	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. <i>British Journal of Haematology</i> , 2021 , 192, 853-868	4.5	5
63	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2021 , 137, 1154-1165	2.2	18
62	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. <i>PLoS Medicine</i> , 2021 , 18, e1003454	11.6	4
61	Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. <i>Advances in Therapy</i> , 2021 , 38, 1328-1341	4.1	1
60	Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. <i>Leukemia</i> , 2020 , 34, 3091-3096	10.7	13
59	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). <i>Leukemia</i> , 2020 , 34, 1840-1852	10.7	30
58	Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. <i>Blood</i> , 2020 , 136, 1091-1104	2.2	23
57	Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. <i>Haematologica</i> , 2020 , Online ahead of print,	6.6	4

56	The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. <i>Leukemia</i> , 2020 , 34, 604-612	10.7	32
55	Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1617-1628	2.2	12
54	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Haematology, the</i> , 2019 , 6, e616-e629	14.6	26
53	A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results. <i>Blood</i> , 2019 , 134, 1890-1890	2.2	3
52	Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance. <i>Blood</i> , 2019 , 134, 3132-3132 ¹	2.2	3
51	Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimism Trial By Patient Age and Prior Stem Cell Transplant. <i>Blood</i> , 2019 , 134, 3120-3120	2.2	
50	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 57-73	21.7	154
49	Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. <i>Leukemia</i> , 2018 , 32, 102-110	10.7	108
48	Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 7777-7782	11.5	17
47	Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimism Trial. <i>Blood</i> , 2018 , 132, 3278-3278	2.2	4
46	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2018 , 132, 1994-1994	2.2	7
45	Subclonal copy number is associated with prognosis in multiple myeloma. <i>Blood</i> , 2018 , 132, 2465-2469	2.2	21
44	Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. <i>British Journal of Haematology</i> , 2017 , 176, 908-917	4.5	19
43	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). <i>Leukemia</i> , 2017 , 31, 107-114	10.7	81
42	The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCR1 Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM). <i>Blood</i> , 2016 , 128, 4412-4412	2.2	2
41	Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. <i>Blood Cancer Journal</i> , 2016 , 6, e506	7	49
40	Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 1021-32	7.4	21
39	Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients. <i>Blood</i> , 2015 , 126, 189-189	2.2	4

38	Velcade, Vorinostat and Dexamethasone (V2 D) in Relapsed Myeloma: Results of the Phase 2 Muk Four Trial. <i>Blood</i> , 2015 , 126, 1852-1852	2.2	
37	Updates to the guidelines for the diagnosis and management of multiple myeloma. <i>British Journal of Haematology</i> , 2014 , 167, 131-3	4.5	14
36	Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. <i>British Journal of Haematology</i> , 2013 , 162, 107-11	4.5	45
35	The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. <i>British Journal of Haematology</i> , 2010 , 150, 326-33	4.5	56
34	Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. <i>Clinical Cancer Research</i> , 2010 , 16, 1856-64	12.9	109
33	A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. <i>Blood</i> , 2010 , 116, e56-65	2.2	263
32	Liposomal cytarabine in cerebrospinal fluid. <i>British Journal of Haematology</i> , 2009 , 145, 679	4.5	3
31	MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. <i>Haematologica</i> , 2009 , 94, 78-86	6.6	94
30	Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. <i>European Journal of Haematology</i> , 2008 , 81, 432-6	3.8	14
29	Deletions of CDKN2C in multiple myeloma: biological and clinical implications. <i>Clinical Cancer Research</i> , 2008 , 14, 6033-41	12.9	77
28	CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma. <i>Blood</i> , 2008 , 112, 3707-3707	2.2	4
27	The Impact of Constitutional Copy Number Variants in Myeloma. <i>Blood</i> , 2008 , 112, 496-496	2.2	
26	Molecular Characterization of Human Multiple Myeloma Cell Lines by Genome-Wide Profiling Identifies Kinase Pathway Alterations.. <i>Blood</i> , 2008 , 112, 1694-1694	2.2	
25	High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Identifies Multiple Novel Genomic Minimally Deleted Regions in Multiple Myeloma. <i>Blood</i> , 2008 , 112, 625-625	2.2	
24	XBP1 Expression Is An Important Prognostic Factor for Newly Diagnosed Myeloma Patients.. <i>Blood</i> , 2008 , 112, 1686-1686	2.2	
23	Homozygous Deletions Can Be Used to Define a Cell Death Specific Gene Expression Signature Able to Predict Outcome in Myeloma. <i>Blood</i> , 2008 , 112, 2725-2725	2.2	
22	Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. <i>British Journal of Haematology</i> , 2007 , 137, 268-9	4.5	86
21	The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. <i>Haematologica</i> , 2007 , 92, 1149-50	6.6	62

20	Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. <i>Blood</i> , 2007 , 110, 3291-300	2.2	121
19	Thalidomide Combinations Improve Response Rates; Results from the MRC IX Study.. <i>Blood</i> , 2007 , 110, 3593-3593	2.2	29
18	Integration of Gene Mapping and Expression Arrays Identifies Mechanisms by Which Genes Are Dysregulated as a Result of Copy Number Loss and Gain Associated with IgH Translocations in Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 395-395	2.2	1
17	The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients.. <i>Blood</i> , 2007 , 110, 2727-2727	2.2	0
16	Thalidomide in Combination with Idarubicin, Dexamethasone and Etoposide (TIDE) Is an Effective Oral Combination in Heavily Pre-Treated Myeloma Patients.. <i>Blood</i> , 2007 , 110, 4841-4841	2.2	
15	Genome-Wide Identification of Gene Expression Networks Affected by Genomic Changes in Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 2494-2494	2.2	
14	Mutation and Methylation Analysis of WWOX and CYLD on 16q; Potential Tumor Suppressor Genes in Myeloma.. <i>Blood</i> , 2007 , 110, 2473-2473	2.2	
13	Screening of Homozygous Deletions Identifies Key Deregulated Genes and Pathways in Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 2474-2474	2.2	
12	An Integrated Pharmacogenomic Strategy for the Definition of Thalidomide Response Signatures in Presenting Cases of Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 2493-2493	2.2	
11	The combination of cyclophosphamide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2335-8	1.9	38
10	Advances in oral therapy for multiple myeloma. <i>Lancet Oncology, The</i> , 2006 , 7, 316-25	21.7	34
9	Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. <i>Blood</i> , 2006 , 108, 1733-43	2.2	163
8	Fine Mapping and Expression Analysis of Chromosome 1 with the Aim of Defining Critically Deregulated Genes Important in the Pathogenesis of Myeloma.. <i>Blood</i> , 2006 , 108, 112-112	2.2	1
7	The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).. <i>Blood</i> , 2006 , 108, 3537-3537	2.2	5
6	Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.. <i>Blood</i> , 2006 , 108, 3555-3555	2.2	2
5	Abnormalities of 16q in Multiple Myeloma Are Associated with Poor Prognosis: 500K Gene Mapping and Expression Correlations Identify Two Potential Tumor Suppressor Genes, WWOX and CYLD.. <i>Blood</i> , 2006 , 108, 110-110	2.2	
4	Sub-Classification of Hyperdiploid Myeloma Using Global Gene Expression Profiling and SNP-Based Mapping Arrays.. <i>Blood</i> , 2006 , 108, 3390-3390	2.2	
3	Insights into the Basis of Chromosomal Imbalances during the Clonal Evolution of Multiple Myeloma Using SNP Array Analysis.. <i>Blood</i> , 2005 , 106, 621-621	2.2	

- 2 Identification of Collaborating Oncogenic Events Leading to Disease Progression in Myeloma Cases with a t(4;14) and t(11;14) Using SNP and Gene Expression Arrays.. *Blood*, **2005**, 106, 1542-1542 2.2
- 1 Status of Chromosome 13 in Multiple Myeloma: Integrated Approach Using SNP Mapping Array and Gene Expression Array.. *Blood*, **2005**, 106, 1563-1563 2.2